BRPI0513793A - pharmaceutically acceptable compound or salt thereof, method of treating a condition in a mammal, pharmaceutical formulation, and pharmaceutical composition - Google Patents

pharmaceutically acceptable compound or salt thereof, method of treating a condition in a mammal, pharmaceutical formulation, and pharmaceutical composition

Info

Publication number
BRPI0513793A
BRPI0513793A BRPI0513793-4A BRPI0513793A BRPI0513793A BR PI0513793 A BRPI0513793 A BR PI0513793A BR PI0513793 A BRPI0513793 A BR PI0513793A BR PI0513793 A BRPI0513793 A BR PI0513793A
Authority
BR
Brazil
Prior art keywords
treating
condition
pharmaceutically acceptable
mammal
salt
Prior art date
Application number
BRPI0513793-4A
Other languages
Portuguese (pt)
Inventor
Mark T Bilodeau
Zhicai Wu
John Hartnett
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0513793A publication Critical patent/BRPI0513793A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, MéTODO DE TRATAMENTO DE UMA CONDIçãO EM UM MAMìFERO, FORMULAçãO FARMACêUTICA, E, COMPOSIçãO FARMACêUTICA A presente invenção refere-se a compostos tendo a estrutura de Fórmula (I) útil como inibidores de canal de potássio para tratar arritmias cardíacas.COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, METHOD OF TREATING A CONDITION IN A MAMMER, PHARMACEUTICAL FORMULATION, AND, PHARMACEUTICAL COMPOSITION The present invention relates to compounds having the structure of Formula (I) useful as potassium inhibitors. treat cardiac arrhythmias.

BRPI0513793-4A 2004-07-29 2005-07-25 pharmaceutically acceptable compound or salt thereof, method of treating a condition in a mammal, pharmaceutical formulation, and pharmaceutical composition BRPI0513793A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59218104P 2004-07-29 2004-07-29
PCT/US2005/026334 WO2006028590A1 (en) 2004-07-29 2005-07-25 1,1,2,2-tetra (hetero) arylethanes or 1,1,2-tri (hetero) aryl-2-heterocyclylethanes as potassium channel inhibitors

Publications (1)

Publication Number Publication Date
BRPI0513793A true BRPI0513793A (en) 2008-05-13

Family

ID=35613661

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513793-4A BRPI0513793A (en) 2004-07-29 2005-07-25 pharmaceutically acceptable compound or salt thereof, method of treating a condition in a mammal, pharmaceutical formulation, and pharmaceutical composition

Country Status (15)

Country Link
KR (1) KR20070043985A (en)
AR (1) AR049847A1 (en)
BR (1) BRPI0513793A (en)
CR (1) CR8876A (en)
EC (1) ECSP077208A (en)
IL (1) IL180846A0 (en)
MA (1) MA28980B1 (en)
MX (1) MX2007001188A (en)
NO (1) NO20071107L (en)
PE (1) PE20060382A1 (en)
RU (1) RU2344134C2 (en)
TW (1) TW200607493A (en)
UA (1) UA88018C2 (en)
WO (1) WO2006028590A1 (en)
ZA (1) ZA200700477B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311003A (en) * 2009-03-18 2016-02-10 麦迪库瑞国际公司 Transdermal pharmaceutical preparation and administration of tirofiban
ES2675314T3 (en) 2012-06-11 2018-07-10 Bristol-Myers Squibb Company Phosphoramic acid prodrugs of 5- [5-phenyl-4- (pyridin-2-ylmethylamino) quinazolin-2-yl] pyridin-3-sulfonamide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003201273A1 (en) * 2002-01-04 2003-07-30 Poseidon Pharmaceuticals A/S Potassium channel modulators

Also Published As

Publication number Publication date
RU2344134C2 (en) 2009-01-20
CR8876A (en) 2007-08-28
PE20060382A1 (en) 2006-05-15
ZA200700477B (en) 2009-08-26
MX2007001188A (en) 2007-03-21
WO2006028590A1 (en) 2006-03-16
ECSP077208A (en) 2007-02-28
TW200607493A (en) 2006-03-01
RU2007107408A (en) 2008-09-10
KR20070043985A (en) 2007-04-26
UA88018C2 (en) 2009-09-10
NO20071107L (en) 2007-04-19
IL180846A0 (en) 2007-06-03
MA28980B1 (en) 2007-11-01
AR049847A1 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
DK1780197T3 (en) 5-Substituted 2-phenylamino-benzamides as MEK inhibitors
BRPI0515500A (en) pyridazine derivatives for stearoyl coa desaturase inhibition
EA201101672A1 (en) SUBSTITUTED DERIVATIVES OF AMINOISAL ACID AS NEPRILISIN INHIBITORS
MX340965B (en) Combinations for the treatment of diseases involving cell proliferation.
BRPI0517567A (en) compound or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, pharmaceutical composition, uses of a compound or a pharmaceutically acceptable salt, solvate, or derivative thereof and a pharmaceutical composition, and process for preparing a compound
EA201001455A1 (en) Pyridine and pyrazine as PI3K inhibitors (phosphatidylinositin kinase-3)
EA200702387A1 (en) IMIDAZOCHINOLINES AS LIPIDKINASE INHIBITORS
BRPI0507198A (en) bisarylurea derivatives
MX2009004475A (en) Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same.
ECSP067076A (en) DERIVATIVES OF PIRIMIDINA UREA AS INHIBITORS OF QUINASA
EA200971081A1 (en) PURINUM DERIVATIVES AND THEIR APPLICATION AS A TALL-SIMILAR RECEPTOR MODULATORS 7
BRPI0606793A8 (en) compound or a pharmaceutically acceptable salt thereof, process for the preparation and use thereof, methods for inhibiting trk activity, treating or prophylaxis cancer, and producing an antiproliferative effect in a warm-blooded animal and pharmaceutical composition
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
AR067495A1 (en) PHARMACEUTICAL COMPOSITIONS AND PROCEDURE DRY EYE DISORDER TREATMENTS
SV2009003299A (en) USED DIHYDROPIRIDINE DERIVATIVES AS INHIBITORS OF PROTEIN QUINASE
BRPI0512193B8 (en) pharmaceutically acceptable compound or salt, pharmaceutical composition, and use of the compound or salt
DE602005013793D1 (en) THIAZONE DERIVATIVES WITH VAP-1-HEMMENDER EFFECT
BRPI0514390A (en) the enantiomer of a compound or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, use thereof, methods for treating cancer, to produce an eg5 inhibitory effect on a warm-blooded animal and to treat disease, and, composition. pharmaceutical
TW200639159A (en) Treatment of pain
BR0309343A (en) Compound, pharmaceutical composition, use of a compound, and method of treating or prophylaxis of human diseases or conditions.
BRPI0508392A (en) Materials and Methods for Treating Coagulation Disorders
BR0309342A (en) Compound, pharmaceutical composition, use of a compound, and method of treating or prophylaxis of human diseases or conditions.
DE602005010744D1 (en) PIPERAZINYLPYRIDINE DERIVATIVES AS AGENTS AGAINST ADIPOSITAS
NO20076357L (en) Azabicyclic heterocycles as cannabinoid receptor modulators
BRPI0617655A2 (en) compound or a pharmaceutically acceptable salt thereof, or an optical isomer thereof, use of a compound, and pharmaceutical formulation

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.